SCHEMBL7417868

SCHEMBL7417868

c1ccc2c(c1)CC1(CCCCC1)O2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.41
ATM Q13315 2/20 0.41
HTT P42858 1/20 0.41
SIGMAR1 Q99720 2/20 0.41
DRD2 P14416 1/20 0.39
HTR2A P28223 1/20 0.39
ALDH1A1 P00352 2/20 0.38
TRPM8 Q7Z2W7 1/20 0.36
EGFR P00533 1/20 0.36
BRAF P15056 1/20 0.36
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
POLB P06746 1/20 0.35
LMNA P02545 1/20 0.35
ALOX12 P18054 1/20 0.35
CYP2D6 P10635 2/20 0.35
TSHR P16473 2/20 0.35
CYP2C19 P33261 2/20 0.35
CYP1A2 P05177 1/20 0.35
PKM P14618 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10192226 1.00 KDM4E (0.41) KDM4EATMHTTSIGMAR1DRD2
SCHEMBL7858958 0.98 SIGMAR1 (0.41) KDM4EATMHTTSIGMAR1DRD2
SCHEMBL22032186 0.90 SIGMAR1 (0.44) ATMSIGMAR1DRD2HTR2ATRPM8
SCHEMBL863351 0.83 OPRD1 (0.44) SIGMAR1DRD2HTR2ALMNACYP2D6
SCHEMBL3560241 0.82 SIGMAR1 (0.57) SIGMAR1DRD2HTR2ATRPM8MAOA
SCHEMBL24203777 0.81 SIGMAR1 (0.42) ATMSIGMAR1DRD2HTR2ATRPM8
SCHEMBL231585 0.81 OPRD1 (0.49) SIGMAR1DRD2HTR2ALMNACYP2D6
SCHEMBL2743253 0.79 KMT2A (0.49) SIGMAR1DRD2HTR2ATRPM8KMT2A
Hydrochloric Acid SCHEMBL10502202 0.79 OPRD1 (0.48) SIGMAR1DRD2HTR2ALMNACYP2D6
SCHEMBL8812382 0.79 HTR2A (0.44) SIGMAR1DRD2HTR2AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260102124-A1 PREDICTION FUNNEL FOR GENERATION OF HYPO- AND HYPER-GLYCEMIC ALERTS BASED ON CONTINUOUS GLUCOSE MONITORING DATA DEXCOM INC (US) 2026-04-16 US disclosed
EP-4685813-A2 PREDICTION FUNNEL FOR GENERATION OF HYPO- AND HYPER GLYCEMIC ALERTS BASED ON CONTINUOUS GLUCOSE MONITORING DATA DexCom, Inc. (US) 2026-01-28 EP disclosed
US-12400325-B2 Lumbar spine anatomical annotation based on magnetic resonance images using artificial intelligence THE UNIVERSITY OF HONG KONG (CN) 2025-08-26 US disclosed
US-20250086794-A1 METHOD AND SYSTEM FOR CALCULATING MYOCARDIAL INFARCTION LIKELIHOOD BASED ON LESION WALL SHEAR STRESS DESCRIPTORS PIE MEDICAL IMAGING B V (NL) 2025-03-13 US disclosed
US-12190504-B2 Method and system for calculating myocardial infarction likelihood based on lesion wall shear stress descriptors PIE MEDICAL IMAGING B.V. (NL) 2025-01-07 US disclosed
EP-4247263-B1 METHOD AND SYSTEM FOR CALCULATING MYOCARDIAL INFARCTION LIKELIHOOD BASED ON LESION WALL SHEAR STRESS DESCRIPTORS PIE MEDICAL IMAGING BV (NL) 2024-10-02 EP disclosed
CN-118679524-A Predictive funnel for generating a hypoglycemic alarm and a hyperglycemic alarm based on continuous glucose monitoring data 德克斯康公司 2024-09-20 CN disclosed
CN-118660868-A Calcium channel blockers and methods of screening 解明岐 2024-09-17 CN disclosed
EP-4427234-A1 PREDICTION FUNNEL FOR GENERATION OF HYPO- AND HYPER GLYCEMIC ALERTS BASED ON CONTINUOUS GLUCOSE MONITORING DATA Dexcom, Inc. (US) 2024-09-11 EP disclosed
CN-116568218-B Method and system for calculating probability of myocardial infarction based on lesion wall shear stress descriptor 帕伊医疗成像有限公司 2024-04-30 CN disclosed
EP-0560929-A4 1994-08-31 EP disclosed
EP-0561989-A4 1994-03-09 EP disclosed
EP-0561989-A1 COMPOUNDS THAT INHIBIT COMPLEMENT AND/OR SUPPRESS IMMUNE ACTIVITY T CELL SCIENCES, INC. (US) 1993-09-29 EP disclosed
EP-0560929-A1 SYNERGISTIC COMPOSITIONS OF SOLUBLE COMPLEMENT RECEPTORS AND COMPOUNDS THAT INHIBIT COMPLEMENT AND/OR SUPPRESS IMMUNE ACTIVITY T CELL SCIENCES, INC. (US) 1993-09-22 EP disclosed
WO-1992010096-A1 COMPOUNDS THAT INHIBIT COMPLEMENT AND/OR SUPPRESS IMMUNE ACTIVITY T CELL SCIENCES, INC. (US) 1992-06-25 WO disclosed
WO-1992010205-A1 SYNERGISTIC COMPOSITIONS OF SOLUBLE COMPLEMENT RECEPTORS AND COMPOUNDS THAT INHIBIT COMPLEMENT AND/OR SUPPRESS IMMUNE ACTIVITY T CELL SCIENCES, INC. (US) 1992-06-25 WO disclosed
WO-1991016888-A1 SPIRO[BENZOFURANCYCLOALKANE]CARBOXAMIDES AS 5HT3 ANTAGONISTS RHONE-POULENC RORER INTERNATIONAL (HOLDINGS), INC. (US) 1991-11-14 WO disclosed
US-4910323-A Chlorination using n-chlorosuccinimide HOECHST ROUSSEL PHARMACEUTICALS, INC. (US) 1990-03-20 US disclosed
US-4847414-A INTERMEDIATES FOR ANTIDEPRESSANTS, ANALGESICS HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) 1989-07-11 US disclosed
US-4404221-A ANALGESICS AND ATNIDEPRESSANTS HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1983-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260102124-A1 PREDICTION FUNNEL FOR GENERATION OF HYPO- AND HYPER-GLYCEMIC ALERTS BASED ON CONTINUOUS GLUCOSE MONITORING DATA SLC2A8, SLC2A4, SLC5A2 KDM4E 4505/4885ATM 1956/4885HTT 2595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.